With immunology and inflammation blockbusters like AbbVie’s Skyrizi and Rinvoq reeling in nearly $7 billion combined in the ...
The Vitiligo market presents opportunities through 18+ companies developing 20+ pipeline drugs, with a focus on novel approaches. Key phases include Phase III (Afamelanotide), Phase II (VYN201), and ...
Sometimes big breakthroughs in science come from very small changes, curiosity, and more than a little luck. A new study from ...
One of the FDA’s potential approvals this month could break an existing monopoly in the treatment space for a rare growth ...
Nektar Therapeutics develops novel immunomodulatory drugs targeting autoimmune diseases and oncology. Click here to read why ...
Phase 2a data support oral C5aR inhibitor INF904 as a potentially transformational and best-in-class immunomodulatory agent, indicating strong ...
GlobalData on MSN
Lilly to advance alternative obesity candidate to Phase III
Eli Lilly is advancing its obesity treatment candidate, which is an alternative to glucagon-like peptide-1 receptor agonists ...
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) Q3 2025 Earnings Call Transcript November 12, 2025 Acumen Pharmaceuticals, Inc.
Adequate management of COPD is important because hospitalisation for an acute exacerbation of COPD (AECOPD) is associated ...
Pfizer Inc. ( PFE) Discusses Clinical Development Strategy for 4404 Bispecific Antibody in Oncology November 10, 2025 8:30 AM EST ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback